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Structural variation (copy number variation [CNV] including deletion and duplication, translocation, inversion) of chromosomes has
been identiﬁed in some individuals with autism spectrum disorder (ASD), but the full etiologic role is unknown. We performed
genome-wide assessment for structural abnormalities in 427 unrelated ASD cases via single-nucleotide polymorphism microarrays
and karyotyping. With microarrays, we discovered 277 unbalanced CNVs in 44% of ASD families not present in 500 controls (and
re-examined in another 1152 controls). Karyotyping detected additional balanced changes. Although most variants were inherited,
we found a total of 27 cases with de novo alterations, and in three (11%) of these individuals, two or more new variants were observed.
De novo CNVs were found in ~7% and ~2% of idiopathic families having one child, or two or more ASD siblings, respectively. We also
detected 13 loci with recurrent/overlapping CNV in unrelated cases, and at these sites, deletions and duplications affecting the same
gene(s) in different individuals and sometimes in asymptomatic carriers were also found. Notwithstanding complexities, our results
further implicate the SHANK3-NLGN4-NRXN1 postsynaptic density genes and also identify novel loci at DPP6-DPP10-PCDH9 (synapse
complex),ANKRD11,DPYD, PTCHD1, 15q24, among others, for a role in ASD susceptibility. Ourmost compelling result discovered CNV
at 16p11.2 (p ¼ 0.002) (with characteristics of a genomic disorder) at ~1% frequency. Some of the ASD regions were also common to
mental retardation loci. Structural variants were found in sufﬁciently high frequency inﬂuencing ASD to suggest that cytogenetic
and microarray analyses be considered in routine clinical workup.Introduction
Autism (MIM 209850) is a neurodevelopmental disorder
that manifests in the ﬁrst three years of life. The group of
pervasive developmental disorders (PDDs), also termed au-
tism spectrum disorders (ASDs), includes autism as well as
PDD-not otherwise speciﬁed (PDD-NOS) and Asperger’s
disorder. The three core characteristics of the ASDs are
impairments of reciprocal social interactions, problems in
communication, and a restricted range of behaviors and
interests. Asperger’s disorder differs from autism in that
individuals have an absence of clinically signiﬁcant cogni-
tive and language delay. ASDs are observed in all popula-
tions with an incidence of 6 cases per 1000, with about
four times more males diagnosed than females.1 The esti-
mated prevalence of autism in siblings is 5%–10%.2
ASDs are etiologically heterogeneous. They are associated
with a recognized cause in about 10% of cases, most com-The Ammonly with fragile X (MIM 300624) and Rett syndrome
(MIM312750), tuberous sclerosis (MIM191100), and other
medical genetic conditions. Heritability estimates for ASDs,
as determined from twin and family studies, are ~90%,3
and linkage scans have mapped candidate risk loci.4
Based on a recent systematic review, cytogenetically
detectable chromosome abnormalities are found in 7.4%
(129/1749) of ASD cases with a range from 0% to 54%.5,6
The highest occurrence of events is observed in syndromic
forms of ASD.6 Balanced translocations and inversions
accounted for 17% (22/129) of rearrangements. Whereas
the most frequent anomaly observed is maternally derived
duplication of chromosome 15q11–q13 in 1%–3% of
cases,7 little is known about the proportion of inherited
compared to spontaneous karyotypic changes at other
sites. With chromosome abnormalities as the initial step
to identify ASD candidate loci, mutations have most
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Table 1. Summary of CNV in ASD and Controls
Popgen Controls Autism Probands
All CNVs All CNVs Autism Specifica
Full Stringentb Full Stringentb Full Stringentb
# Samples 500 500 427 427 427 427
# CNVs 3695 1558 3396 1315 889 277
CNV/Genomec 7.4 3.1 8.0 3.1 2.1 0.65
Mean/Median Size (kb) 315/151 470/224 390/162 603/219 518/121 1082/194
% Gain/Loss 59/41% 70/30% 58/42% 62/38% 61/39% 57/43%
Overlapping CNV/Loci (%)d 3005/333 (81%) 1226/142 (78%) 2734/277 (80%) 983/94 (74%) 398/122 (44%) 31/13 (11%)
>1 Mb CNV(%) 343 (9%) 250 (16%) 339 (10%) 212 (16%) 63 (7%) 32 (12%)
a Not seen in the initial 500 controls. There were 50 probands run in a previous study with the Affymetrix 10K array.4 The 10K array detected five different
CNVs in five individuals. Of these putative CNVs, three were confirmed by the current 500K experiments, one was a false positive, and one had no probe
coverage on the 500K platform so its status is unknown.
b Stringent data set as called by>1 algorithms or arrays. Analysis with dChip was performed in batches of ~100 probands. For CNAG version 2.0, we set the
reference pool to include all samples and performed an automatic batch pair-wise analysis with sex-matched controls. For GEMCA, we used two designated
DNA samples (NA10851 and NA15510) as references for pair-wise comparison to all proband experiments. We further filtered these results by including only
those CNVs that were common to both pair-wise experiments. In all instances, CNVs were merged if they were detected in the same individual by more than
one algorithm with the outside probe boundaries.
c CNV/genome breakdown by algorithm: dChip Merged (3.0/genome), CNAG Merged (5.6/genome), GEMCA (5.5/genome). Validation experiments with
q-PCR and FISH are described in the text. Another form of validation comes from examining the trios where we can demonstrate inheritance in 48 (maternal
is 25, paternal is 23) of the autism-specific stringent data set. Also from the trios, 148 confirmed regions (inheritance assignment) in the stringent data set
that overlap with controls (maternal is 65, paternal is 83).
d Represents the total number of overlapping and/or recurrent CNVs, the number of overlapping/CNV loci, and the percentage of overlapping CNVs, out of
the total data set.22q13,8,9 two neuroligin (NLGN3 and NLGN4) genes on
the X chromosome,10 and the neurexin 1 gene on chro-
mosome 2p16.4,11,12 Recent data have also revealed that
submicroscopic copy number variants (CNVs) can have
a role in ASD,4,13 and de novo CNVs seem to be
a more common risk factor in sporadic compared with
familial forms of ASD.13,14
Our objective was to determine the potential contribu-
tion of all forms of genomic structural variation in ASD.
We therefore used both high-resolution microarray tech-
nologies and karyotyping, allowing detection of both un-
balanced and balanced as well as submicroscopic and cyto-
genetically visible structural variants. We also built a new
Autism Chromosome Rearrangement Database (ACRD)
allowing integration of ours and all other molecular in-
formation with the wealth of karyotypic data gathered
over the years.15 We have identiﬁed several new candidate
ASD-susceptibility loci, some of which encode proteins
that are known to function within the synapse. Although
the association of these variants with ASD is often compel-
ling, there are many genotypic and phenotypic complex-
ities. Our data, however, do indicate that high-resolution
microarray analysis can be a powerful tool for clinical
categorization and diagnosis in ASD.
Material and Methods
DNA Samples and Population Structure
The study included 427 ASD families (Table S1 available online).
All cases met Autism Diagnostic Interview-Revised (ADI-R) and
AutismDiagnostic Observation Schedule (ADOS) criteria on a clin-478 The American Journal of Human Genetics 82, 477–488, Februarical best estimate.16 Of these, 32 carried a cytogenetic chromo-
some rearrangement, 18 were detected through this study by
karyotyping 313 of 413 idiopathic samples, and 14 were already
known to carry karyotypic anomalies (Tables S1 and S2). Affected
and unaffected siblings were also assessed, and 56% (237/427) had
one child (simplex) and 44% (189/427) had more than one child
(multiplex) with ASD. This ratio of multiplex to simplex is artiﬁ-
cially elevated, reﬂecting our earlier interest in analyzing families
in linkage studies.4 Most cases were screened for fragile X muta-
tions (75%), and if detected, they were not included. Experiments
were performed on blood DNA (80%) or otherwise lymphoblasts.
Population ancestry was estimated via STRUCTURE17 (Table S1).
Affymetrix GeneChip Human Mapping 500K Array
and Karyotyping Experiments
For each sample, approximately 500,000 SNPs were genotyped
with the combined two-chip Affymetrix NspI and StyI GeneChip
Human Mapping Commercial or Early Access Arrays according
to standard protocols.9,18 Data have been submitted to the Gene
Expression Omnibus database (accession GSE9222). Karyotypes
were generated by standard clinical diagnostic protocols.
Characterization of Copy Number Variation
NspI/StyI array scans were analyzed for CNV content with
a combination of DNA Chip Analyzer (dChip),4,19 Copy Number
Analysis for GeneChip (CNAG),20 and Genotyping Microarray
based CNVAnalysis (GEMCA)21 (Table 1).
Controls and the ACRD
Initial control samples consisted of (1) CNVs observed in 500
Europeans from the German PopGen project22 and (2) entries in the
Database of Genomic Variants (containing 8006 CNVs at 3933
loci).23 A CNV was considered ASD speciﬁc if it was >10 kb,y 2008
Figure 1. Genome-wide Distribution of CNVs
CNVs from the Autism Chromosome Rearrangement Database (ACRD) are plotted to the right of each chromosome (black). CNV data from
the autism-specific stringent data set from the current study are shown to the left of the chromosome and is categorized as de novo
(blue), overlapping/recurrent (green), CNVs overlapping with structural variation from the ACRD (yellow), and singleton CNVs (red).
Note that five CNVs belong to both de novo and the recurrent categories and these are denoted by an asterisk (see Tables 2 and 3).
All CNV data sets are described in Table 1 and the characteristics of the 277 CNVs depicted here are described in Table S3. The raw
data from all are present in the Gene Expression Omnibus database.contained at least three probes, and at least 20% of its total length
was unique when compared to the controls. To further test
whether CNVs found in probands were speciﬁc to ASD, we also
compared to CNV found in a cohort of 1152 nondisease controls
of European origin from the Ontario population.24 In addition, we
established the ACRD that had 834 putative CNVs or breakpoints
mapped to the genome.
CNV Validation Experiments and Balanced
Rearrangement Breakpoint Mapping
PCR validation of CNV calls was performed with Quantitative
Multiplex PCR of short ﬂuorescent fragments (QMPSF) or SYBR-
Green I-based real-time quantitative PCR (qPCR) with controls at
the ACCN1, CFTR, or FOXP2 loci. At least two independent
qPCR assays were required for conﬁrmation of a CNV. Balanced
rearrangements were mapped primarily with FISH.25 Themicrodel
program26 was used to score CNV losses.The AmStatistical Analysis
To assess the signiﬁcance of the frequency of recurrent CNVs in
ASD probands and controls, a 2-sided Fischer’s exact test was
used.
Results
Structural Variation Characteristics in ASD Cases
We initially tested 427 ASD probands for CNV content in-
cluding 413 idiopathic cases (18 of which were found by
karyotyping to have rearrangements) and 14 others that
were enrolled based on prior knowledge of a cytogenetic
abnormality (Table S1). We used the Affymetrix 500k SNP
array because it provided the highest resolution screen
available for both SNP genotype and CNV data. By using
the SNPs, we could categorize the ancestry of the sampleserican Journal of Human Genetics 82, 477–488, February 2008 479
Table 2. Twenty-Seven ASD Cases with De Novo Rearrangements
FamID Sex Typea Chromosomeb Size (bp)c CNV Genesd Phenotype Comments
1 SK0181-004 M CHR (SPX) 3p14.1-p13 (a) 5,346,900 loss 13 genes IQ/LOFe 78, language mod delay,f speech 2þ,g
RB2þ,h dysmorph 3þ,i congenital unilateral
sensorineural hearing loss
t(6;14)(q13;q21) (k) N/A none 11 genes
2 SK0152-003 M CHR (MPX) 3p25.1-p24.3 (a) 1,409,600 loss 12 genes LOF 31, RL/ELj mod/sev delay, speech 3þ,
RB2þ, dysmorph 0, hypotonia affecting FM &
GM development
5p15.31-p15.2 (a) 3,429,389 loss 8 genes
12q12 (a) 422,842 loss 4 genes
t(5;7)(p15p13) (k) N/A none CDH18
3 SK0215-006 M CHR (SPX) 1p21.3 (a) 1,092,500 loss DPYD whole LOF 31, language sev delay, RB3þ, dysmorph
N/A
4 SK0205-004 F CHR (SPX) 5p15.33-p15.2 (k) 13,800,984 loss 46 genes IQ/LOF & language mild delay, RB1þ,
dysmorph 3þ, Cri du Chat syndrome
5 SK0083-003 M CHR (SPX) 7q31.1-q31.31 (k) 11,023,507 loss 25 genes IQ/LOF 56, language sev, speech 3þ, RB1þ,
dysmorph 3þ, febrile seizures
6 SK0131-003 F CHR (SPX) 7q31.1-q32.2 (k) 15,486,722 loss >50 genes IQ/LOF 74, RL/EL mod/sev delay, speech 2þ,
RB2þ, dysmorph 3þ, microcephaly
7 SK0243-003 M CHR (SPX) 15q23-q24.2 (k) 4,289,500 loss >50 genes LOF severely impaired, language sev delay,
RB2þ, dysmorph 3þ, severe scoliosis, hiatal
hernia
8 SK0073-003 F CHR (SPX) 15q11.2-q13.3 (k) 11,922,600 gain >50 genes IQ/LOF 49, RL/EL mod delay, RB3þ,
dysmorph N/A, premature (34 wks),
hypotonia
9 SK0245-005 M CHR (SPX) 15q11.2-q13.3 (k) 11,871,747 gain >50 genes IQ/LOF 47, RL/EL sev delay, RB3þ, dysmorph
N/A
10 SK0218-003 F CHR (MPX) 18q21.32-q23 (k) 20,358,999 loss >50 genes LOF severely impaired, RL/EL nonverbal,
RB3þ, dysmorph 3þ, seizures, microcephaly,
strabismus, hypotonia, cleft palate, club feet
11 NA0039-000 F CHR (SPX) 22q13.31-q13.33 (k) 3,231,700 loss 41 genes LOF< 40, language sev delay, RB0, dysmorph
2þ, hypotonia, mega cisterna magna,
submucous cleft palate, single umbilical
artery; father has balanced reciprocal
translocation (14;22), proband inherited
der(22), sister with ADHD also has
unbalanced karyotype with der(14)
12 NA0097-000 F CHR (SPX) Xp22.33- p22.31 (a) 5,825,311 loss 21 genesþNLGN4 IQ/LOF 117, language average, speech 2þ,
RB1þ, dysmorph 0, carries maternal
balanced reciprocal 11;12 translocation
13 SK0283-003 F CHR (SPX) 47,XX, ring chr1 (k) N/A gain >50 genes IQ/LOF 30, RL/EL sev delay, RB2þ, dysmorph
3þ, microcephaly, blood dyscrasia, failure to
thrive
14 SK0195-003 M CHR (SPX) t(5;8;17)(q31.1;
q24.1;q21.3) (k)
N/A none 5 genes IQ/LOF unknown, language nonverbal,
RB2þ, dysmorph 3þ, bifid uvula
15 SK0306-004 F SPX 2q32.1 (a) 97,130 loss None IQ/LOF 68, RL/EL mild delay, speech 2þ,i
RB2þ, dysmorph 3þ, severe hypotonia
16 NA0002-000 M SPX 7q36.2 (a) 66,462 loss DPP6 exonic IQ/LOF unknown, RL/EL sev delay, RB3þ,
dysmorph 0
17 SK0262-003 M SPX 8p23.3 (a) 791,089 gain DLGAP2 exonic IQ/LOF 68, RL/EL mod delay, RB4þ,
dysmorph N/A
18 MM0278-003 M SPX 12q24.21-q24.33 (a) 18,218,000 gain >50 genes IQ/LOF 24, language sev delay, speech 1þ,
RB3þ, dysmorph 1þ, seizures; scoliosis,
lower limb anomaly
19 NA0067-000 M SPX 16q24.3 (a) 265,667 loss ANKRD11 exonic IQ/LOF unknown, language mod delay,
RB3þ, dysmorph 2þ, motor delay,
alloimmune ITP
20 MM0088-003 F MPX 16p11.2 (a) 675,829 loss 28 genes IQ/LOF 82, RL/EL mod delay, RB3þ,
dysmorph 0
21 SK0102-004 M SPX 16p11.2 (a) 432,600 gain 24 genes IQ/LOF 39, RL/EL sev delay, speech 2þ,
RB3þ, dysmorph 2þ, epilepsy, scoliosis,
diaphragmatic hernia
22 SK0019-004 M SPX 16p11.2 (a) 675,829 loss 28 genes IQ/LOF 93, RL/EL average, speech 2þ, RB3þ,
dysmorph 1, hyperphagia and severe obesity
23 SK0244-003 M SPX 21q22.3 (a) 353,936 gain 4 genes IQ/LOF 80, RL/EL mild delay, RB1þ,
dysmorph N/A
24 MM0109-003 F SPX 20q13.33 (a) 1,427,661 gain 44 genes IQ/LOF 27, language nonverbal, RB3þ,
dysmorph 1þ22q13.33 (a) 276,702 loss 13 genesþSHANK3480 The American Journal of Human Genetics 82, 477–488, February 2008
Table 2. Continued
FamID Sex Typea Chromosomeb Size (bp)c CNV Genesd Phenotype Comments
25 SK0119-003k M MPX 22q11.21 (a) 2,771,300 loss >50 genes IQ/LOF 77, RL/EL mod/sev delay, dysmorph
3þ, velocardiofacial syndrome
26 SK0297-003 M SPX-MZ 22q11.21 (a) 4,281,262 gain >50 genes IQ/LOF 75, RL/EL average, speech 1þ, RB3þ,
dysmorph 2þ, seizures, MZ twin (discordant
for ASD)
27 SK0306-004 F SPX Xp11.23-p11.22 (a) 4,643,367 gain >50 genes IQ/LOF 68, RL/EL mild delay, speech 2þ,
RB2þ, dysmorph 3þ, severe hypotonia
a Probands with abnormal karyotypes (CHR) (1–14) are separated from probands belonging to simplex (SPX) and multiplex (MPX) families with normal
karyotypes (15–27). Families are grouped and sorted based on simplex (SPX), multiplex (MPX), and chromosomal abnormalities (CHR). Simplex families
with affected monozygotic twins are denoted as SPX-MZ. Some cases here are also recurrent and appear in Table 3 and some of the family pedigrees
are shown in Figure 2 and Figure S2. For multiplex families, the de novo events were not detected in affected siblings.
b De novo event detected by either karyotype (k) or microarray (a).
c All de novo CNV detected by the array were validated with qPCR, whereas translocations and larger deletions/duplications detected by karyotyping were
confirmed by FISH. In all cases where an unbalanced change occurs, CNV size is based on array results. The breakpoints have not been accurately defined,
and CNVs may be smaller or larger than posted.
d If the CNV intersects only a single gene (suggesting that it may disrupt the gene), the term ‘‘exonic’’ is used, and if the CNV encompasses the entire gene,
the term ‘‘whole’’ is used. The term ‘‘intronic’’ is used for CNV that overlaps noncoding parts of a single gene.
e IQ/LOF, level of functioning denotes average of Vineland Social, Communication, and daily living scores and nonverbal IQ, when available.
f Language was rated as average, nonverbal, mild, mod (moderately delayed), or sev (severely delayed).
g Speech refers to the severity of impaired speech intelligibility, most likely resulting from oral motor apraxia (1þ, mild; 2þ, moderate; 3þ, severe
unintelligibility; or 0, intelligible speech).
h RB: repetitive behavior score was derived from ADI and ADOS ratings (1þ, mild; 2þ, moderate; 3þ, severe repetitive behaviors; or 0, no repetitive
behaviors).
i Dysmorphology scores were based on anthropometric measurement abnormalities and qualitative features documented either by a clinical geneticist or
a developmental pediatrician. Anomalies were reviewed by a single clinical geneticist and assigned score: 0, not dysmorphic; 1þ, mild; 2þ, moderate; 3þ,
severe degree of dysmorphism. Children with known genetic syndromes received a score of 3þ. N/A, not assessed for dysmorphic features.
j RL, receptive language; EL, expressive.
k SK0119-003 originally entered the study with an ASD diagnosis but upon re-examination after CNV detection was assessed to be below cutoffs for ASD.(to guide selection of controls) and found 90.3%, 4.5%,
4.5%, and 0.7% to have European, European/mixed,
Asian, or African backgrounds, respectively.
To maximize CNV discovery, we used three calling algo-
rithms (Figure S1) and merged sample-speciﬁc results
between them to identify a ‘‘full’’ data set of 3396 indepen-
dent CNVs (~8 CNVs per genome, mean size 390 kb) (Table
1). To minimize potential false positives, we generated
a second data set whereby a CNV needed to be detected
by two or more algorithms and/or on both the NspI or
StyI microarrays (see Figure S2 for representative data).27
This ‘‘stringent’’ data set contained 1315 CNVs (~3 CNVs
per genome, mean size 603 kb), of which we were able to
validate 10/10 (5 deletions and 5 duplications) randomly
selected CNVs via q-PCR. In total, we validated 97% (89/
92) of CNVs tested in the stringent data set.
We then examined 500 European control samples for
their CNV content and found similar numbers of CNVs
(3695 in the full and 1558 in the stringent data set)
to those in the ASD cases (Table 1). This suggested that
germline chromosome instability was not a signiﬁcant
contributing mechanism. We also compared the ASD
CNVs against the 500 European controls and the Database
of Genomic Variants (a repository of structural variation
in ‘‘nondisease’’ populations)23 to establish ASD-speciﬁc
CNVdata sets.Most of our subsequent analysis then focused
on the 277 CNVs in our stringent autism-speciﬁc category,The Amwhich mapped across all the 22 autosomes and X (but not
Y) chromosome (Figure 1; Table S3). Additional ASD-rele-
vant CNV data are also found in the other categories (Table
1; Table S2; and in the ACRD).
Wide-ranging prevalence frequencies of cytogenetically
detectable chromosomal abnormalities in ASD and the in-
ability of microarray scans to ﬁnd balanced abnormalities
prompted us to also perform karyotyping. Karyotyping
(and FISH) also provided the ability to characterize the chro-
mosomal context (e.g., ring chromosomes) of some of the
CNV regions, something not possible with microarrays
alone.We therefore examined consecutive idiopathic cases
where blood was available and found that 5.8% (18/313)
cases had balanced (11) or unbalanced (7) karyotypes.
We note that all unbalanced karyotypic changes described
in this study were also found by microarray analysis and
are included in the CNV statistics, and further that micro-
array analysis conﬁrmed all balanced karyotypic changes
(i.e., there were no additional gains or losses at the break-
points below cytogenetic resolution). The genomic charac-
teristics of all CNVs are shown in the ACRD (see Figure S3
as one example). We note that from our data, a CNV loss
and gain will typically equate to a standard deletion or du-
plication, but they could also be more complex.18 In some
cases, a duplication of only part of a gene could lead to its
disruption, and there are also positional effects on gene
expression to consider.28erican Journal of Human Genetics 82, 477–488, February 2008 481
Table 3. Recurrent and Overlapping Loci in ASD
Chromosome FamID Sex Typea Size (bp)b CNV Origin Genesc Phenotype Comments
1 2q14.1 SK0147-003 F SPX 478,370 loss paternal DPP10 exonic IQ/LOFd unknown, RL/ELe sev delay, RB2þ,f
dysmorph 3þ,g neurofibromatosis type 1,
abnormal EEG
SK0288-003 F SPX-MZ 105,120 gain paternal DPP10 intronic IQ/LOF 73, RL/EL average/mild delay,
RB 2þ, dysmorph N/A
2 2q32.1 SK0306-004 F SPX 97,130 loss de novo none IQ/LOF 68, RL/EL mild delay, speech 2þ,h
RB2þ, dysmorph 3þ, severe hypotonia
NA0030-000 M SPX 112,323 loss maternal none IQ/LOF 69, RL/EL mod delay, RB2þ,
dysmorph 1þ, seizures, medicated for OCD,
motor incoordination
3 6q22.31 MM0220-003 M MPX 318,000 gain paternal PLN whole IQ/LOF 82, language average, dysmorph 2þ,
high myopia, fine motor difficulties
NA0025-000 M SPX 293,989 gain paternal PLN whole IQ/LOF unknown, language: regression/mild
delay, RB2þ, dysmorph 0
4 7q36.2 SK0190-003 M SPX 1,780,000 gain maternal DPP6 whole IQ/LOF 55, RL/EL sev delay, speech 2þ,
RB1þ, dysmorph N/A, parents 1st cousins
SK0115-003 M SPX 274,000 gain unknown DPP6 exonic IQ/LOF 86, RL/EL average, RB2þ, ysmorph N/A,
SK0058-003 M MPX 16,788 gain maternal DPP6 intronic IQ/LOF 111, RL/EL average, RB1þ, ysmorph N/A
NA0002-000 M SPX 66,462 loss de novo DPP6 exonic IQ/LOF unknown, RL/EL severe delay,
RB3þ, dysmorph 0
5 8q11.23 SK0143-003 M SPX 285,200 gain unknown UNQ9433 whole,
RB1CC1 exonic
IQ/LOF 65, RL/EL sev delay, speech 2þ,
RB2þ, dysmorph 2þ, seizures, hypoplastic
left heart syndrome, left hemidiaphragm
paralysis
MM0236-004 M MPX 271,679 gain unknown RB1CC1 exonic IQ/LOF 84, language average, RB1þ,
dysmorph 0, central auditory processing
difficulty
6 9p24.1 SK0270-003 M SPX 38,900 loss unknown none IQ/LOF 67, RL/EL mild/mod delay,
speech 1þ, RB3þ, dysmorph N/A
MM0103-003 M MPX 34,950 loss paternal none IQ/LOF 100, language mild delay, speech 0,
RB2þ, dysmorph 0, twin preg (other twin lost in
1st trimester), premature (34 wks with
respiratory distress syndrome), club feet
7 11p12 MM0272-003 M MPX 262,938 loss maternal none IQ/LOF 74, language mild delay, speech 3þ,
RB2þ, dysmorph N/A, seizures, unilateral
congenital ptosis
SK0167-003 F MPX 192,846 loss unknown none IQ/LOF 62, RL/EL average/mild delay, speech
apraxia 2þ, dysmorph N/A
8 13q21.32 SK0023-003 M SPX 189,438 gain unknown PCDH9 intronic IQ/LOF 82, RL/EL mod/sev delay, speech 2þ,
RB2þ, dysmorph N/A; seizures
MM0299-003 F MPX 172,401 gain paternal PCDH9 intronic IQ/LOF 43, language nonverbal, RB2þ,
dysmorph 0, hypotonia, gags/chokes, fine motor
delay
9 15q11.2-q13.3 SK0073-003 F CHR 11,922,600 gain de novo >50 genes IQ/LOF 49, RL/EL mod delay, RB3þ, dysmorph
N/A, premature (34 wks)
SK0245-005 M CHR 11,871,747 gain de novo >50 genes IQ/LOF 47, RL/EL sev delay, RB3þ,
dysmorph N/A
10 16p12.2 MM0109-003 F SPX 1,246,288 gain maternal 8 genes IQ/LOF 27, language nonverbal, RB3þ,
dysmorph 1þ
MM0289-003 F MPX 802,555 loss maternal 5 genes IQ/LOF 45, language delay, RB2þ, dysmorph 0
11 16p11.2 NA0133-000 F SPX 525,319 gain maternal 29 genes IQ/LOF & language moderate delay, speech 2þ,
RB1þ, dysmorph 0, early motor delay
SK0102-004 M SPX 432,600 gaini de novo 24 genes IQ/LOF 39, RL/EL sev delay, speech 2þ,
RB3þ, dysmorph 2þ, epilepsy, congenital
diaphragmatic hernia
MM0088-003 F MPX 675,829 loss de novo 32 genes IQ/LOF 82, RL/EL mod delay, RB3þ,
dysmorph 1þ
SK0019-004 M SPX 675,829 loss de novo 32 genes IQ/LOF 93, RL/EL average, speech 2þ,
RB3þ, dysmorph 1þ, hyperphagia and severe
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Table 3. Continued
Chromosome FamID Sex Typea Size (bp)b CNV Origin Genesc Phenotype Comments
12 22q11.2 SK0119-003j M MPX 2,771,300 loss de novo >50 genes IQ/LOF 77, RL/EL mod/sev delay, dysmorph 3þ,
velocardiofacial syndrome
SK0091-004 F MPX 4,281,262 gain paternal >50 genes IQ/LOF 92, RL/EL average/mod delay, RB3þ,
dysmorph 0, placental insufficiency
SK0297-003 M SPX-MZ 4,281,262 gain de novo >50 genes IQ/LOF 74, language average; RB3þ,
dysmorph 2þ, seizures, MZ twin (discordant
for ASD)
SK0323-003 M MPX 743,100 gain unknown 7 genes IQ/LOQ 43, language sev delay, RB4þ,
dysmorph N/A
13 22q13.31 SK0123-004 M MPX 601,528 gain maternal none IQ 93, language mod delay, RB4þ, dysmorph 0,
nonidentical triplet, Hirschsprung disease
MM0102-003 M MPX 80,380 loss maternal none IQ/LOF 60, language mild delay, dysmorph 0,
weakness & hypotonia of arms
a Probands are ordered by chromosome location. Families are grouped based on simplex (SPX), multiplex (MPX), and chromosomal abnormalities (CHR).
Simplex families with affected monozygotic twins are denoted as SPX-MZ. The de novo cases also appear in Table 2 and some of the family pedigrees are
shown in Figure 2 and Figure S2.
b All recurrent and overlapping CNVs were detected by the array validated with qPCR. The breakpoints have not been accurately defined, and CNVs may be
smaller or larger than noted.
c If the CNV intersects only a single gene (suggesting that it may disrupt the gene), the term ‘‘exonic’’ is used, and if the CNV encompasses the entire gene,
the term ‘‘whole’’ is used. The term ‘‘intronic’’ is used for CNV that overlaps noncoding parts of a single gene.
d IQ/LOF (level of functioning) denotes average of Vineland Social, Communication and daily living scores and nonverbal IQ, when available.
e Language (RL, receptive language; EL, expressive language) was rated as average, nonverbal, or mild, mod (moderately), or sev (severely) delayed.
f RB (repetitive behavior) score was derived from ADI and ADOS ratings (1þ, mild; 2þ, moderate; 3þ, severe repetitive behaviors; or 0, no repetitive
behaviors).
g Dysmorphology scores were based on anthropometric measurement abnormalities and qualitative features documented either by a clinical geneticist or
a developmental pediatrician. Anomalies were reviewed by a single clinical geneticist and assigned score 0, not dysmorphic; 1þ, mild; 2þ, moderate; 3þ,
severe degree of dysmorphism. Children with known genetic syndromes received a score of 3þ. N/A, not assessed for dysmorphic features.
h Speech refers to the severity of impaired speech intelligibility, most likely resulting from oral motor apraxia (1þ, mild; 2þ, moderate; 3þ, severe un-
intelligibility).
i CNV is called by only one algorithm.
j SK0119-003 originally entered the study with an ASD diagnosis but upon re-examination after CNV detection was assessed to be below cutoffs for ASD.De Novo, Overlapping/Recurrent, and Inherited
Structural Variants
We initially prioritized structural variants found in ASD
cases to possibly be etiologic if they were not in our initial
control set and (1) de novo in origin (27 cases) (Table 2), (2)
overlapping (27 cases at 13 loci) in two or more unrelated
samples (Table 3), (3) recurrent (same breakpoints) in two
or more unrelated samples (four cases at two loci) (Table 3),
or (4) inherited (the remainder). We found CNVs at pre-
viously reported ASD loci: NLGN4 and 22q11.2, 15q11–
q13, SHANK3, and NRXN1 in categories 1, 2, 3, and 4,
respectively. ASD structural variants found in controls
(e.g., NRXN1) could also be involved.
By testing random families, a de novo CNV rate of 7.1%
(4/56) and 2.0% (1/49) was observed in our idiopathic sim-
plex andmultiplex families, respectively, similar to rates in
another project.13 This is likely a minimum value because
many smaller CNVs will be beyond detection with the
current technology. The literature13,29 and our previous
work18 have shown a <1% spontaneous CNV mutation
rate in nondisease samples. Regarding balanced alter-
ations, there was parental information for 13 of 18 cases
discovered to carry cytogenetic anomalies (Table S1), and
7 (6 simplex, 1 multiplex) of these were de novo in origin.
Because only 1/7 (from a simplex family) was balanced and
directly interrupting a gene, we estimate that this class ofThe Amrearrangements had much less of a contribution than
CNVs to the total rate of de novo and inherited structural
variation in our ASD cohort.
Our collective data identiﬁed 27 de novo cases (Table 2),
and in threeof these, twoormoreeventswere identiﬁed.No-
tably in family SK0152 (Figure 2A), there were four de novo
events. In MM0109 (Figure 2B), there were two de novo
CNVs, one leading to haploinsufﬁciency of SHANK3.
The 13 loci where overlapping ASD-speciﬁc CNVs were
found are more likely to have a role in ASD susceptibility
because they arise in two or more unrelated families. In
six loci, gains and losses were observed at the same locus
(Table 3), suggesting that general gene dysregulation may
be involved. In those cases with shared CNVs not over-
lapping with a known medical genetic locus (see below),
phenotypic re-examination yielded no obvious genotype-
phenotype correlation beyond a trend for larger sporadic
abnormalities to generally have a more complex clinical
presentation. We also note that in the ‘‘full’’ data set, there
are 397 overlapping CNVs at 122 loci, among which other
bona ﬁde candidate ASD loci may exist.
By using q-PCR or by assessing SNP patterns, we con-
ﬁrmed 196 inherited CNVs (90 maternal and 106 pater-
nal). No subgrouping of these demonstrated obvious
parent-of-origin effects (the two chromosome 15q11–q13
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did detect a 160 kb deletion in a male inherited from
a carrier mother, leading to a null PTCHD1 in the proband
and his dizygotic twin brother (Figure 2C). We also found
instances where apparently balanced inherited translo-
cations were accompanied by de novo deletions elsewhere
in the genome in the offspring (e.g., DPYD; Figure 2D).
Candidate ASD-Susceptibility Genes
and Loci Identiﬁed
To further validate our ﬁndings, we compared our de novo
and recurrent/overlapping CNVs from ASD cases to an ad-
ditional 1152 matched controls. This sample consists of
samples from Ontario, Canada, of European origin.24 We
analyzed these in an identical manner to our ASD data
and were unable to ﬁnd CNV matching identically to the
27 de novo cases nor to the 13 recurrent/overlapping
ASD cases, further emphasizing the potential importance
Figure 2. Examples of Complexities of
Structural Variants Observed in ASD
Families
Males are denoted by squares and females
by circles. The size of each de novo or
inherited event is shown below each family
member. Arrows identify the proband,
open shapes are unaffected, and filled
have ASD diagnosis (gray denotes develop-
mental delay but not a definitive ASD diag-
nosis). Diamonds indicate number of older
unaffected siblings of unspecified gender.
For ASD cases, probands may have multiple
de novo events (A), including rearrange-
ments overlapping genes known to be
associated with ASD such as SHANK3 (B).
Probands may also inherit chromosome X
deletions (at PTCHD1) from female carriers
(C) or have an inherited translocation in
addition to an unrelated de novo deletion
(D). Overlapping events in unrelated pro-
bands may be either de novo (E) or in-
herited (F) at the DPP6 locus. Recurrent
de novo events in unrelated probands
may also be either losses (G) or gains (H)
at chromosome 16p11.2. Additional ASD
families with CNVs at DPP6 and 16p11.2
are shown in Figures S4 and S5, respec-
tively.
of these regions. There was, however,
one new CNV overlapping the DPP6
locus found in this control set (see
below).
New ASD candidates identiﬁed
were those with a structural change
(either de novo, found in two or
more unrelated ASD cases, or for the
X chromosome an allele being trans-
mitted maternally from an unaffected
carrier) speciﬁc to that gene, including ANKRD11,
DLGAP2, DPP6, DPP10, DPYD, PCDH9, and PTCHD1 (Ta-
bles 2 and 3). As previously mentioned, NLGN4, SHANK3,
and NRXN1 were also identiﬁed. The PCDH9 and NRXN1
genes are also found as CNVs in controls in the Database
of Genomic Variants. This suggests that there could also
be other important CNVs that are not included in the
277 ASD-speciﬁc variants on which we based most of our
analyses.
Additional positional candidate genes identiﬁed were
those found interrupted by balanced cytogenetic break-
points including NEGR1, PIP5K1B, GABRG1, KLHL3, STK3,
ST7, and SATB2 (Table S2). Moreover, 77 CNVs in our strin-
gent data set overlapped with the ACRD, providing a
second line of evidence for involvement (Figure 1). For ex-
ample, a 4.6 Mb de novo duplication at Xp11.23–11.22 was
detected in a female SK0306-004 (Table 2) and a male in484 The American Journal of Human Genetics 82, 477–488, February 2008
the database.30 There is a wealth of other data that needs
further analysis at the population level, such as the ﬁnding
of an ~100 kb deletion at 2q37.3 (previously shown to be
involved in ASD6,7 that occurs in twice the frequency in
ASD cases compared to controls) (Table S2).
DPP6 and DPP10 emerge as being positional and func-
tional candidates. DPP6 (~1.5 Mb in size at 2q14.1) and
DPP10 (~1.3 Mb at 7q36.2) code for accessory transmem-
brane dipeptidyl peptidase-like subunits that affect the
expression and gating of Kv4.2 channels (KCND2). Kv4.2
channels function in regulation of neurotransmitter release
and neuronal excitability in the glutamatergic synapse31 at
the same sites where SHANK3 and theNLGN gene products
are found. Moreover, we have mapped autism balanced
breakpoints near KCND2 at 7q31 (see the ACRD).25
For DPP10, there are inherited CNV gains and losses
(Table 3; Figure S4). De novo and inherited CNVs were
found at the multitranscript DPP6 gene (CNV in 4/427
ASD probands versus 1/1652 controls [initial 500 controls
plus 1152 additional controls; Fischer exact test p value ¼
0.016]). A 66 kb de novo loss encompassing exons 2 and 3
is found in a male in family NA0002 (Figure 2E). In family
SK0190, the male proband and an unaffected female sib-
ling both carry a CNV gain inherited from an unaffected
mother (Figure 2F) that encompassed the entire DPP6. A
270 kb gain is found in SK0115-003 that extends across
the ﬁrst exon (which may disrupt the functional gene),
and SK0058-003 carries a maternally inherited 16 kb
intronic CNV gain (Figure S4).14
Medical Genetics
We identify structural variants overlapping loci involved in
medical genetic conditions including Waardenburg Type
IIA (MIM 193510; 3p14.1), speech and language disorder
(MIM 602081; 7q31), mental retardation (MR) (15q23–q24,
16p11.2), and velocardialfacial syndrome (VCFS) (MIM
192430; 22q11.2), among others (Tables 2 and 3; Table
S2). Identiﬁcation of the structural variant at these loci
led to clinical reassessment and either identiﬁcation or
reﬁnement of the diagnosis, for additional syndromic
features. Other instances (e.g., SK0186-PTCHD1 deletion)
(Figure 2C) prompted retesting of the entire family and
eventually a diagnosis of mild ASD in a previously undiag-
nosed sibling. This family would therefore move from
a simplex to multiplex designation, underscoring the
need for cautious interpretation of our statistics in any
medical genetic application.
The identiﬁcation of a de novo deletion (2.7 Mb) at
22q11.2 in two brothers with ASD led to their re-examina-
tion and diagnosis for VCFS. The retesting also further
deﬁned the siblings to be at opposite ends of the ASD spec-
trum (Figure S5). Larger duplications (4.3 Mb) of this same
region in two other ASD families (SK0289 and SK0091) do
not cause VCFS (Table 3). However, in SK0091, the variant
was inherited from a normal father and was not found in
an affected male sibling. Other studies also reveal differen-The Amtial phenotypes, some having ASD associated with differ-
ent duplications and deletions at this locus.32
We also discovered a recurrent ~500 kb duplication at
16p11.2 in two ASD families (SK0102 and NA0133) (Fig-
ure 2; Figure S5). The same region was recently shown
to be involved in mental retardation, aortic valve devel-
opment, and seizure disorder.33 As with DPP6/DPP10
and 22q11.2, there are carriers of these structural variants
without ASD. At the same loci, we also detected a recurrent
676 kb de novo deletion in two ASD families (MM0088 and
SK0019). Family SK0019 is a simplex family with the dele-
tion in the proband (Figure S5), whereas in family
MM0088, the deletion is detected in only one of two
ASD siblings (Figure 2G). This brings a combined discovery
rate of 4/427 16p11.2 CNVs in ASD and 0/1652 controls (2-
sided Fischer’s exact test p value¼ 0.002). We note that the
16p11.2 deletions and duplications may be reciprocal
events, and we are testing this by ﬁne-mapping the break-
points.
Discussion
Our genome-wide analysis of structural variation yields
many new results indicating that chromosomal abnormal-
ities have a substantial role in ASD. In light of these and
other ﬁndings,4,13,34 we recommend that genomic analy-
sis, in particular with high-resolution microarrays, be
used in research studies of ASD and possibly in clinical
assessment once we understand what the implications of
these variants are. Such structural variation data could ini-
tially serve to focus clinical examination in a search for un-
detected syndromes. In cases where the loci detected show
high penetrance such as haploinsufﬁciency of SHANK38,9
and 16p11.2, clinical diagnostic testing could be consid-
ered.
In our cohort, we observed that ~7% of randomly se-
lected idiopathic cases harbor de novo genomic CNV rear-
rangements that are detectable by the microarray platform
we used (including ASD cases with balanced translocation
or inversion changes that affect genes increases the num-
ber slightly). Of these, we found that ~11% of cases actually
carry two or more de novo events. Moreover, in other fam-
ilies (and in some cases in the general population), there
were non-ASD carriers of the variants, as well as ASD sib-
lings without the variant (Figure 2). These observations,
coupledwith the newly recognized abundance of structural
variants in the genome35 having a comparatively high new
mutation rate,29 cautions against assigning causation to all
de novo rearrangements found. Certainly in some in-
stances additional independent risk factors need to be con-
sidered, including those being genetic, epigenetic, environ-
mental, or stochastic in origin.36 Our ﬁnding of X-linked
CNVs being maternally transmitted to males and that
most structural variants detected on X are inherited from
parentsmay contribute to explain gender prevalence differ-
ences and the high degree of heritability in ASD.erican Journal of Human Genetics 82, 477–488, February 2008 485
With the genome-wide scanning approach, we have
identiﬁed numerous new putative ASD loci (Tables 2 and
3; Figure 1). Three themes that emerge include the identi-
ﬁcation of (1) loci that often contain genes functioning
in the postsynaptic density (PSD), (2) and/or chromosomal
regions previously shown to be involved inmental retarda-
tion, and (3) new loci where general dysregulation of gene
expression may be involved.
First, we found CNVs that further implicate the SHANK3,
NLGN4, andNRXN1-PSD genes and also identify others in-
cludingDPP6 andDPP10 (and PCDH9, RPS6KA2, RET from
the larger data set). Neuroligins have been shown to bind
to the SHANK3 scaffolding protein and are required for
the maturation of glutamatergic synapses. Moreover, the
neurexins are ligands of the neuroligins, thus supporting
a potential pathogenic construct of a network of interre-
lated molecules, from the trans-synaptic interaction
between the neurexins and neuroligins to the PSD com-
plex that includes SHANK3. Given that DPP6 and DPP10
are gating channels regulating neurotransmitter release,
a functional complex emerges, in which perturbations at
a number of potential PSD molecules acting alone or in
combination may lead to ASD.37,38
Second, we identiﬁed at least two ASD loci (15q24,
16p11.2) that overlap with knownMR sites,33,39,40 suggest-
ing that some of the genes causing MR also cause autism
(we also found inherited CNVs at three other MR loci:
IDS, IL1RAPL1, and TSPAN7). We did not detect structural
variants at other chromosome loci associated with anoma-
lies in syndromic forms of ASD such as 7q11.23 (MIM
609757) and 17p11.2 (MIM 610883), most likely because
we limited our cases to more strictly deﬁned ASD.
The 16p11.2 CNV region is particularly interesting be-
cause it is found at near to 1% frequency in our autism
cohort and not controls. It also exhibits characteristics of
a genomic disorder, including being ﬂanked by a pair of
segmental duplications with >99% identity, which likely
mediate the deletion and duplication events through non-
allelic homologous recombination (Figure S3). We found
both duplication and deletions associated with ASD at
this locus. Although no obvious genotype-phenotype cor-
relation is so far obvious in the four families we have iden-
tiﬁed (Figure S5B), the deletion may be more penetrant be-
cause some unaffected individuals carry the duplication.
Twenty-four genes map to the CNV interval, including
ﬁve postsynaptic density (PSD) genes (DOC2A, ALDOA,
MAPK3, CORO1A, and CDIPT) and two candidates for sei-
zure (SEZ6L2 and QPRT). The fact that both duplications
and deletions exert phenotype suggests that some genes
in the interval are sensitive to dosage.
Third, we discovered six unrelated ASD cases that had
either CNV gains or losses in unrelated individuals at the
same locus (including 16p11.2) (Table 3). This suggests
that ﬁne tuning of gene expression of critical genes in
these regions can be crucial for the development of speech
and language and/or social communication, as seems to be
the case for SHANK38,9 and genes in the Williams-Beuren486 The American Journal of Human Genetics 82, 477–488, Februarsyndrome locus (MIM 194050).41 In some cases, duplica-
tion of the Williams-Beuren syndrome region also exhibits
an ASD-like phenotype (MIM 609757).
Our understanding of the full etiologic role of structural
variation in ASD will require genomic and phenotypic
analyses of more cases (and their families) and population
controls.42 To achieve the desired numbers, integration of
multiple data sets will likely be necessary; hence, our estab-
lishing the ACRD resource as a ﬁrst step. From our current
data, it is already apparent that for a proportion of individ-
uals, it will be possible to describe their ASD based on the
underlying structural characteristics of their genome. The
detection rate of structural variation and ability to discern
the associated outcome will only increase as new higher-
resolution genome-scanning methods become available
and accessible.
Supplemental Data
Supplemental data include ﬁve ﬁgures and three tables and can be
found with this article online at http://www.ajhg.org/.
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